Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...

Cathie Wood-led Ark Invest made significant trades involving CRSP, TXG, RBLX, ACHR, NU, ADYEY, ACCD, and AVAV.

PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day.

Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...

Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.

Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...

CRISPR Therapeutics AG (CRSP) stock price is 41.21 and CRISPR Therapeutics AG (CRSP) 10-day simple moving average is 41.52. CRISPR Therapeutics AG (CRSP) stock price is 41.21 and CRISPR ...

A £1.65 million treatment has been approved for use for some NHS patients, offering hope of a cure to those with an inherited ...